Skip to main content

Irit Ben-Chelouche

Executive Director / Director of Business Development, Harvard Medical School

Displaying: 1 - 10 of 34 Results

Isolating live cells after high-throughput, long-term, time-lapse microscopy

Researchers led by Johan Paulsson have engineered a high-throughput microfluidic device for multigenerational culturing, imaging, and tracking of single-cell lineages. The platform is highly customizable and is compatible with many cell types,…

Investigators

  • Johan Paulsson

Machine learning to accelerate diagnostics and therapeutics for COVID-19

The COVID-19 pandemic demands a rapid response of science, diagnostics, and therapeutics. Debora Marks’ lab at Harvard Medical School aims to accelerate those efforts using predictive models of the SARS-CoV2-19 sequences and 3D structures. The lab’s…

Investigators

  • Debora Marks

Novel adjuvants to enhance adaptive immune response of vaccines

Researchers in the lab of Ulrich von Andrian have discovered a novel adjuvanting behavior of a clinically approved and well-tolerated class of medicines known as bisphosphonates. The team is hoping to collaborate with manufacturers of COVID-19…

Investigators

  • Ulrich H. von Andrian

Exo-site Enzyme Inhibitor Discovery Platform for Oncology Therapeutics

A startup emerging from David Liu's lab intends to commercialize a small-molecule enzyme inhibitor discovery platform to generate more potent drugs with higher specificity. (Image credit: Rose Lincoln/Harvard Staff Photographer.)Off-target drug…

Investigators

  • David R. Liu

Autophagy Enhancers for the Treatment of Neurodegeneration

An emerging startup from Junying Yuan's lab intends to develop three classes of small molecules for the treatment of neurodegenerative diseases. (Image credit: iStock.)There are currently no disease-modifying treatments available for…

Investigators

  • Junying Yuan

Continuous directed evolution of aminoacyl-tRNA synthetases to alter amino acid specificity and enhance activity

DESCRIPTION Functions of various biotherapeutics can often be enhanced by modifying individual amino acid residues. However, the current approaches rely on existing natural amino acid chemistry. Approaches that provide new chemical “handles” will…

Investigators

  • David R. Liu

Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers

DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…

Investigators

  • David R. Liu

Modulating the Blood-Brain Barrier (BBB) to enable delivery of drugs and development of therapeutics

The blood–brain barrier (BBB) helps maintain a constant, optimal environment for neuronal function through a combination of barriers and selective transport systems that regulate the passage of wanted and unwanted molecules. While important for…

Investigators

  • Chenghua Gu

Hba-a1 knockout mice

Homozygous Hba-a1 (hemoglobin alpha, adult chain 1) knockout mice (129S-Hba-a1tm1Led/J) were developed by HHMI Investigator Dr. Philip Leder and his lab at Harvard Medical School. While the mice are viable and fertile, they develop anemia with…

Investigators

  • Philip Leder

Trpa1 conditional knockout mice

The mouse strain 129S-Trpa1tm2Kykw/J was developed by Kelvin Kwan in the laboratory of HHMI Investigator David Corey at Harvard Medical School. Trpa1 conditional knockout animals were generated by flanking the exons that code for the pore domain of…

Investigators

  • Kelvin Y. Kwan
  • David P. Corey

Page 1 of 4